SRI-37330 | CAS#2322245-42-9 | TXNIP expression inhibitor

SRI-37330 HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 463768

CAS#: 2322245-49-6 (HCl)

Description: SRI-37330 hydrochloride is a novel inhibitor of TXNIP expression, decreasing glucagon secretion and action and blocking hepatic glucose output, reversing obesity- and STZ-induced diabetes and hepatic steatosis.

Chemical Structure

SRI-37330 HCl

CAS# 2322245-49-6 (HCl)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 463768
Name: SRI-37330 HCl
CAS#: 2322245-49-6 (HCl)
Chemical Formula: C16H20ClF3N4O2S
Exact Mass: 0.00
Molecular Weight: 424.867
Elemental Analysis: C, 45.23; H, 4.75; Cl, 8.34; F, 13.41; N, 13.19; O, 7.53; S, 7.55

Price and Availability

Size	Price	Availability
1mg	USD 80	Ready to ship
5mg	USD 150	Ready to ship
10mg	USD 250	Ready to ship
25mg	USD 550	Ready to ship
50mg	USD 950	Ready to ship
100mg	USD 1650	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 2322245-49-6 (HCl) 2322245-42-9 (free base)

Synonym: SRI-37330 hydrochloride; SRI37330 hydrochloride; SRI 37330 hydrochloride; SRI-37330 HCl; SRI37330 HCl; SRI 37330 HCl;

IUPAC/Chemical Name: N-((1-(6-(trifluoromethyl)quinazolin-4-yl)piperidin-3-yl)methyl)methanesulfonamide hydrochloride

InChi Key: SIWGSSRKYJTJTF-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H19F3N4O2S.ClH/c1-26(24,25)22-8-11-3-2-6-23(9-11)15-13-7-12(16(17,18)19)4-5-14(13)20-10-21-15;/h4-5,7,10-11,22H,2-3,6,8-9H2,1H3;1H

SMILES Code: CS(=O)(NCC1CN(C2=C3C=C(C(F)(F)F)C=CC3=NC=N2)CCC1)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#S22S07C31

QC Data:

View QC data: current batch, Lot#S22S07C31

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor.
In vitro activity:	Transient transfection experiments showed that SRI-37330 inhibited the activity of the human TXNIP promoter in INS-1 cells by ~70% (Fig. 1b), consistent with inhibition at the transcriptional level. SRI-37330 also inhibited endogenous TXNIP mRNA expression as shown by 7-point dose-response qRT-PCR assays (Fig. 1c), revealing an IC50 of 0.64 μM and no cytotoxicity (Supplemental Table S1a). Similarly, SRI-37330 also inhibited TXNIP protein levels in a dose-dependent manner (Fig. 1d). Reference: Cell Metab. 2020 Sep 1;32(3):353-365.e8. https://pubmed.ncbi.nlm.nih.gov/32726606/
In vivo activity:	Intraperitoneal glucose tolerance tests (GTTs) revealed a consistently and significantly improved glucose tolerance in response to SRI37330 administration (Fig. 3c), whereas insulin tolerance tests (ITTs) remained unaltered (Fig. 3d). Fasting blood glucose was slightly, but significantly lower in SRI-37330-treated mice (Fig. 3e). Notably, while fasting serum insulin levels were unchanged in SRI-37330-treated mice as compared to controls (Fig. 3f), fasting serum glucagon levels were lower (Fig. 3g), suggesting that SRI37330 may also affect glucagon secretion from pancreatic alpha cells. Reference: Cell Metab. 2020 Sep 1;32(3):353-365.e8. https://pubmed.ncbi.nlm.nih.gov/32726606/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	62.5	147.10

Preparing Stock Solutions

The following data is based on the product molecular weight 424.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, Grayson TB, Lu B, Li P, Augelli-Szafran CE, Suto MJ, Kanke M, Sethupathy P, Kim JK, Shalev A. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. doi: 10.1016/j.cmet.2020.07.002. Epub 2020 Jul 28. PMID: 32726606; PMCID: PMC7501995.
In vitro protocol:	1. Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, Grayson TB, Lu B, Li P, Augelli-Szafran CE, Suto MJ, Kanke M, Sethupathy P, Kim JK, Shalev A. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. doi: 10.1016/j.cmet.2020.07.002. Epub 2020 Jul 28. PMID: 32726606; PMCID: PMC7501995.
In vivo protocol:	1. Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, Grayson TB, Lu B, Li P, Augelli-Szafran CE, Suto MJ, Kanke M, Sethupathy P, Kim JK, Shalev A. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. doi: 10.1016/j.cmet.2020.07.002. Epub 2020 Jul 28. PMID: 32726606; PMCID: PMC7501995.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, Grayson TB, Lu B, Li P, Augelli-Szafran CE, Suto MJ, Kanke M, Sethupathy P, Kim JK, Shalev A. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. doi: 10.1016/j.cmet.2020.07.002. Epub 2020 Jul 28. PMID: 32726606; PMCID: PMC7501995.

Your view history

SRI-37330 HCl featured